Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.

@article{Hsueh2002ProlongedSA,
  title={Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.},
  author={Eddy C. Hsueh and Richard Essner and Leland J. Foshag and David W. Ollila and Guy Gammon and Steven J. O'Day and Peter D. Boasberg and Stacey L Stern and Xing Ye and Donald L. Morton},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2002},
  volume={20 23},
  pages={4549-54}
}
PURPOSE The curative effect of surgery in certain patients with metastatic melanoma suggests the presence of endogenous antitumor responses. Because melanoma is immunogenic, we investigated whether a therapeutic cancer vaccine called Canvaxin (CancerVax Corporation, Carlsbad, CA) could enhance antitumor immune responses and thereby prolong survival. PATIENTS AND METHODS Of 263 patients who underwent complete resection of American Joint Committee on Cancer stage IV melanoma, 150 received… CONTINUE READING